Skip to main content

Table 2 SP effect on the incidence of clinical malaria during different periods in Ifakara and Manhiça

From: Varying efficacy of intermittent preventive treatment for malaria in infants in two similar trials: public health implications

Outcome Placebo SP* Protective efficacy p
Events PYAR Rate Events PYAR Rate (95% CI)  
During 1 month after dose 1         
Ifakara 8 21.71 0.37 1 22.21 0.05 87.8% (2.3;98.5) 0.012
Manhiça 13 47.48 0.27 1 49.97 0.02 92.7% (44.2;99.0) < 0.001
Combined effect adjusted by study 21 69.19 0.30 2 72.18 0.03 90.9% (61.0;97.9) < 0.001
During 1 month after dose 2         
Ifakara 6 21.83 0.27 0 22.41 0.00 100% (.;100) 0.004
Manhiça 23 47.33 0.49 10 50.27 0.20 59.0% (13.8;80.5) 0.014
From 1 month after dose 2 until dose 3         
Ifakara 32 100.08 0.32 16 106.04 0.15 52.8% (14.0;74.1) 0.011
Manhiça 92 169.09 0.54 85 183.36 0.46 14.7% (-14.6;36.5) 0.292
During 1 month after dose 3         
Ifakara 14 21.51 0.65 2 22.32 0.09 86.2% (39.4;96.9) 0.001
Manhiça 32 46.94 0.68 16 49.82 0.32 52.7% (13.9;74.1) 0.012
During 6 months from 1 month after dose 3         
Ifakara 51 112.56 0.45 37 120.90 0.31 32.2% (-3.5;55.6) 0.070
Manhiça 107 228.31 0.47 104 239.31 0.43 7.4% (-21.3;29.3) 0.578
  1. *Sulphadoxine-pyrimethamine